Any help is appreciated
So in past research I’ve handled BPC-157, TB500, Selank, Semax, GHK-CU, etc without any major issues during reconstitution. Recently started working with Tesamorelin and have run into some confusing behaviour.
The Tesamorelin is supplied in 20mg lyophilized vials. Based on a lot of discussion online, the research subject was first reconstituted with 2mL bacteriostatic water. Initially everything appeared normal, however after refrigeration the following day the solution had turned into a jelly-like consistency.
Additional bacteriostatic water was then added incrementally and the solution mostly re-dissolved, although not perfectly. Unsure whether this indicates a concentration issue, formulation issue, or instability problem.
After speaking with a few people, it was suggested that Tesamorelin may sometimes require acetic acid solution rather than bacteriostatic water for proper reconstitution. A fresh 20mg vial was therefore reconstituted using 2mL acetic acid solution instead.
This second vial behaved differently and did not gel in the same way, however the resulting solution appeared significantly more irritating/harsh during research application than other peptides previously handled. Post-application there was noticeable localized redness and irritation around the administration site, although it settled down afterwards.
Questions:
- Is the jelly-like behaviour with bacteriostatic water something others have encountered specifically with Tesamorelin?
- Is there a specific type/strength/brand of bacteriostatic water commonly preferred for Tesamorelin research to avoid gelling?
- Does this sound more like a formulation or manufacturing issue?
- If a vial initially gelled with bacteriostatic water but later re-dissolved after adding additional diluent, would most researchers still consider that vial questionable?